Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript
09:37pm, Friday, 09'th May 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Found
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
02:30pm, Friday, 09'th May 2025
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
09:10am, Friday, 09'th May 2025
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago.
IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
07:00am, Friday, 09'th May 2025
Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermati
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
07:00am, Wednesday, 07'th May 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
Why Kymera Therapeutics Stock Crushed it This Week
06:03pm, Friday, 25'th Apr 2025
According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (KYMR -0.86%) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile bi
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?
11:10am, Thursday, 10'th Apr 2025
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
07:00am, Wednesday, 09'th Apr 2025
WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
02:16pm, Friday, 28'th Feb 2025
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
02:48pm, Thursday, 27'th Feb 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Fou
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
09:20am, Thursday, 27'th Feb 2025
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.25 per share a year ago.
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
07:00am, Wednesday, 26'th Feb 2025
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
07:00am, Thursday, 30'th Jan 2025
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medici
